In April 2022, CGT Catapult published the ‘National Cell and Gene Therapy Vision’ for the UK to ensure that the UK remains a world leader in the provision of cell and gene therapies.
This document outlines recommendations for the adaptation of CGT and suggests priorities for creating a sustainable future for the industry. The document addresses the following:
- Outlines how the UK will scale up its manufacturing capacity, building on the work already underway from the Cell and Gene Therapy Catapult in setting out how a UK manufacturing sector will be developed
- Reviews the challenges that cell and gene therapies are likely to pose to health technology assessment bodies and makes recommendations on flexibilities that need to be introduced to ensure their approval, where clinically and cost effective
- Recommends reforms to the reimbursement of advanced therapies to improve access and promote sustainability, including the use of novel pricing and reimbursement approaches
- Sets out how the NHS could develop its data infrastructure to capture the measures that matter to patients, inform continued improvements in clinical practice, and strengthen the real-world evidence base to address the post-launch evidence requirements of ATMPs
- Includes planning on how to increase treatment centre capacity within existing centres, and how to equip further centres to provide advanced therapies in the future – providing a roadmap on how centres can be supported to gain the appropriate accreditation to provide ATMPs going forwards
George Freeman MP, Minister for Science – Research and innovation has said:
“This National Cell and Gene Therapy Vision supports our ambition to cement the UK’s position as a world leader in advanced clinical research and development while helping to accelerate access both for patients to new therapies and researchers to patients.“
Here at Oribiotech, we welcome this vision and strive to continue our work in cell and gene therapy to manufacture brighter futures. For more information on Catapults Vision, take a look here.